Posts Tagged ‘alzheimer’s treatment’

The Latest Outlook On Alzheimer's Disease

The Latest Outlook On Alzheimer’s Disease

More than 5 million Americans have Alzheimer’s disease, and the nonprofit Alzheimer’s Association projects that, barring major advances, 11 million to 16 million will have it by 2050–at an annual cost of $1.1 trillion in today’s dollars. In May, the government announced the first national plan to combat Alzheimer’s, and one focus is the role […]

EliLillyAlzheimer'sDrugShowsPositiveResults

Alzheimer’s Drug Shows Positive Results In Mild Cases

Combined results from two studies of an experimental Alzheimer’s drug suggest it might modestly slow mental decline, especially in patients with mild disease. Taken separately, the studies on the drug — Eli Lilly & Co.’s solanezumab — missed their main goals of significantly slowing the mind-robbing disease or improving activities of daily living. But pooled […]

Alzheimer'sDrugMayLowerLevelsOfBrainPlaque

Studies: Alzheimer’s Drug May Stabilize Brain Plaque

An experimental drug that failed to stop mental decline in Alzheimer’s patients also signaled potential benefit that suggests it might help if given earlier, fuller results of two major studies show. Some patients on the drug had stable levels of brain plaque and less evidence of nerve damage compared to others who were given a dummy treatment, researchers reported […]

TreatmentOptionsForPeopleWithAlzheimer'sDisease

Treatment Options For People With Alzheimer’s Disease

There are more than 5.4 million Americans living with Alzheimer’s disease, a form of dementia, and it is the sixth leading cause of death in the United States. According to the Alzheimer’s Association, people diagnosed with Alzheimer’s live an average of eight years after being diagnosed, though some survive up to 20 years depending on their age and other health conditions. […]

EliLillyAlzheimer'sDrugFailsStudyButShowsPotential

Alzheimer’s Drug Fails Study But Flashes Potential

An Alzheimer’s treatment from Eli Lilly and Co. failed to slow memory decline in two separate patient studies, but the drug did show some potential to help in mild cases of the mind-robbing condition that is notoriously difficult to treat. The Indianapolis drugmaker’s announcement could be a step toward a long-awaited breakthrough in the fight […]